Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4460960 | 1.00 | KCNH2 (0.68) | KCNH2LSS | |
| SCHEMBL4464415 | 1.00 | KCNH2 (0.68) | KCNH2LSS | |
| SCHEMBL4462692 | 0.89 | KCNH2 (0.69) | KCNH2 | |
| SCHEMBL4460200 | 0.89 | KCNH2 (0.69) | KCNH2 | |
| SCHEMBL4458667 | 0.83 | KCNH2 (0.69) | KCNH2 | |
| SCHEMBL4463828 | 0.83 | KCNH2 (0.69) | KCNH2 | |
| SCHEMBL4458669 | 0.83 | KCNH2 (0.69) | KCNH2 | |
| SCHEMBL5399893 | 0.82 | KCNH2 (0.67) | KCNH2 | |
| SCHEMBL4460955 | 0.82 | KCNH2 (0.80) | KCNH2 | |
| SCHEMBL4464408 | 0.82 | KCNH2 (0.80) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507760-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-24 | — | — | US | claimed |
| US-20050165065-A1 | N-type calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2005-07-28 | — | — | US | claimed |
| US-7507760-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-24 | — | — | US | disclosed |
| US-20050165065-A1 | N-type calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165065-A1 | N-type calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | KCNH2 46/4885LSS 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.